Diamyd Medical AB (publ) (DMYD_B) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Diamyd Medical Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.281 Hi, and welcome to this live broadcast from BioStock Studio. 00:00:05.281 -- 00:00:10.291 In Tänselvik, Diarmuid Medical have announced a financing agreement with 00:00:10.291 -- 00:00:14.960 US specialist investors and this morning published their Q2 report. 00:00:14.960 -- 00:00:20.310 We are joined by CEO Ulf Harnedius and CFO Niklas Axelsson, who are here to tell 00:00:20.310 -- 00:00:25.479 us more. And don't forget that the live chat is open, so just send in your questions 00:00:25.479 -- 00:00:30.487 and the gentleman will answer them after a brief presentation. 00:00:30.487 -- 00:00:34.470 And with that, I hand it over to you, Ulf. 00:00:35.475 -- 00:00:40.278 Welcome, everyone, and I'll start off here by giving you 00:00:40.278 -- 00:00:42.201 a brief 00:00:42.201 -- 00:00:47.469 sort of run through the main achievements milestones during this period 00:00:47.469 -- 00:00:52.496 and also some of the upcoming milestones. And then Niklas will follow 00:00:52.496 -- 00:00:57.023 with a bit more of a deep dive into the financials. 00:00:57.023 -- 00:01:00.308 So let's start off here by 00:01:00.308 -- 00:01:05.799 Just a second here. So it's been, as always, a very intense, 00:01:05.799 -- 00:01:10.810 intense period and maybe especially intense now as we are getting close to the first 00:01:10.810 -- 00:01:15.857 interim readout in the phase three trial. So with the milestones that we 00:01:15.857 -- 00:01:20.922 have achieved, first of all, full enrollment in the phase three trial that 00:01:20.922 -- 00:01:25.487 is running in Europe and US. So we now have 321 00:01:25.487 -- 00:01:28.871 patients enrolled and it's now fully randomized. 00:01:28.871 -- 00:01:34.137 And this, I must say, is quite a monumental achievement by ...